EP
NKTR icon

Elkfork Partners’s Nektar Therapeutics NKTR Stock Holding History

Elkfork Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$689K Buy
2,523
+356
+16% +$131K 0.02% 490
2019
Q2 		$1.16M Sell
2,167
-741
-25% -$372K 0.03% 366
2019
Q1 		$1.47M Sell
2,908
-6,918
-70% -$4.1M 0.04% 313
2018
Q4 		$4.84M Buy
9,826
+1,872
+24% +$1.13M 0.14% 152
2018
Q3 		$7.27M Buy
7,954
+7,038
+768% +$6.01M 0.17% 124
2018
Q2 		$671K Buy
916
+624
+214% +$720K 0.02% 446
2018
Q1 		$466K Sell
292
-1,263
-81% -$1.63M 0.01% 545
2017
Q4 		$1.39M Buy
1,555
+265
+21% +$157K 0.04% 299
2017
Q3 		$464K Buy
1,290
+175
+16% +$54.7K 0.01% 507
2017
Q2 		$327K Buy
1,115
+480
+76% +$139K 0.01% 585
2017
Q1 		$223K Buy
635
+64
+11% +$14.4K 0.01% 569
2016
Q4 		$105K Buy
+571
New +$116K ﹤0.01% 728

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Elkfork Partners's NKTR Position: Q3 2019 in Review

Elkfork Partners increased its Nektar Therapeutics (NKTR) stake by 16% in Q3 2019, buying an estimated $131K and bringing the position to 2,523 shares worth $689K. The position accounts for 0.02% of the portfolio, ranked #490.

Elkfork Partners first reported a position in NKTR in Q4 2016 and has held it in 12 quarters since. The position peaked at $7.27M in Q3 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Elkfork Partners held 2,523 shares of Nektar Therapeutics worth $689K as of Q3 2019.
  • Elkfork Partners bought 356 Nektar Therapeutics shares in Q3 2019, an estimated $131K.
  • Nektar Therapeutics made up 0.02% of Elkfork Partners's portfolio in Q3 2019, its #490 holding.
  • Elkfork Partners first reported a position in Nektar Therapeutics in Q4 2016 and has held it in 12 quarters since.
  • Elkfork Partners's Nektar Therapeutics position peaked at $7.27M in Q3 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.